Roy S. Herbst

Also affiliated with Yale University, University of New Haven, Smilow Cancer Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

8.7Author DataRank

Indexed papers

8in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 8 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Papers

Driven by 47 papers — median percentile 84. Top paper: “Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial”.

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30111-x

N/A

6.6DataRank · unranked

541 citations

Kurt A. Schalper, Scott Gettinger, Amit Mahajan, Roy S. Herbst, Anne C. Chiang +19 more

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology(2021)10.1001/jamaoncol.2021.2209

N/A

3.1DataRank · unranked

105 citations

Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.09.013

N/A

2.3DataRank · unranked

79 citations

Mary W. Redman, Susanne M. Arnold, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973

Top 11%

1.9DataRank

Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection

PLoS ONE(2021)10.1371/journal.pone.0243291

Top 12%

1.7DataRank

Top 12%49 citations

Frederick Warner, H. P. Young, Nathan C. Hurley, Rebecca Pulk, Avinainder Singh +21 more

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Nature(2020)10.1038/s41586-020-2588-y

N/A

1.2DataRank · unranked

2312 citations

Patrick Wong, Jon Klein, Tiago B. R. Castro, Julio Silva, Maria E. Sundaram +94 more

Clinical Characteristics and Outcomes for 7,995 Patients with SARS-CoV-2 Infection

medRxiv(2020)10.1101/2020.07.19.20157305

Top 20%

1.0DataRank

Top 20%21 citations

Frederick Warner, H. P. Young, Nathan C. Hurley, Rebecca Pulk, Avinainder Singh +21 more

RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4291

N/A

0.920DataRank · unranked

19 citations

Dejian Zhao, Heather Lazowski, Man Li, Yuping Qian, Laura Abriola +8 more

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-004440

N/A

0.729DataRank · unranked

128 citations

Venkata Nagineni, Arvind Ravi, Ila Datar, Mari Mino–Kenudson, Germán Corredor +11 more

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

The Lancet Oncology(2020)10.1016/s1470-2045(20)30475-7

N/A

0.725DataRank · unranked

125 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +21 more

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.10.002

N/A

0.659DataRank · unranked

13 citations

Mary W. Redman, James Moon, Francesco Agustoni, Roy S. Herbst, Thomas J. Semrad +6 more

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0741

N/A

0.606DataRank · unranked

56 citations

Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst +7 more

Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer

Nature Genetics(2025)10.1038/s41588-025-02351-7

N/A

0.581DataRank · unranked

47 citations

James Monkman, Jonathan Warrell, Ioannis Vathiotis, Katherine Bates, Niki Gavrielatou +11 more

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0251

N/A

0.564DataRank · unranked

42 citations

Jiexin Zhang, Dzifa Y. Duose, Edgar Gonzalez‐Kozlova, Mary W. Redman, Hong Chen +42 more

Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9532

N/A

0.552DataRank · unranked

9 citations

Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick +6 more

Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.11.012

N/A

0.536DataRank · unranked

7 citations

Lisa M. Fucito, Krysten W. Bold, Susan Neveu, Fangyong Li, Alana M. Rojewski +5 more

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.001

N/A

0.524DataRank · unranked

32 citations

Mary W. Redman, Lauren A. Byers, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Longitudinal immunological analyses reveal inflammatory misfiring in severe COVID-19 patients

10.1101/2020.06.23.20138289

N/A

0.510DataRank · unranked

29 citations

Patrick Wong, Jon Klein, Tiago B.R. Castro, Julio Silva, Maria Sundaram +32 more

An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model

Human Genomics(2023)10.1186/s40246-023-00521-4

N/A

0.396DataRank · unranked

13 citations

Reza Aalizadeh, Álvaro J. Santos‐Neto, Wan Ying Tan, Emily A. Davidson, Varvara Nikolopoulou +82 more

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9024

N/A

0.360DataRank · unranked

10 citations

Mary W. Redman, Paul Wheatley‐Price, Bryan A. Faller, Liza C. Villaruz, Larry Corum +10 more

The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials

Clinical Radiology(2020)10.1016/j.crad.2020.09.024

N/A

0.345DataRank · unranked

9 citations

Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, J.J. Lee, Joe Ensor, E.S. Kim +9 more

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)

JCO Clinical Cancer Informatics(2023)10.1200/cci.22.00165

N/A

0.336DataRank · unranked

4 citations

Weijia Fan, Aijin Wang, Riha Vaidya, Mary W. Redman, Scott Gettinger +5 more

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad003

N/A

0.330DataRank · unranked

8 citations

Qian Lu, Mary W. Redman, Susan S. Tavernier, Lori M. Minasian, Ellen V. Sigal +17 more

Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay

Modern Pathology(2024)10.1016/j.modpat.2024.100556

N/A

0.330DataRank · unranked

8 citations

Ioannis Vathiotis, Charles J. Robbins, Nay Chan, Myrto Moutafi, Sneha Burela +6 more

Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.07.024

N/A

0.326DataRank · unranked

5 citations

Xing Hua, Michael C. Wu, Khaled Tolba, Saiama N. Waqar, Konstantin H. Dragnev +10 more

Navigating the Evolving Landscape of EGFR -Mutated NSCLC

New England Journal of Medicine(2026)10.1056/nejme2514042

N/A

0.269DataRank · unranked

5 citations

Roy S. Herbst

A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9060

N/A

0.208DataRank · unranked

3 citations

Mary W. Redman, Jennifer M. Suga, Tareq Al Baghdadi, John L. Villano, Sarah B. Goldberg +6 more

Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9576

N/A

0.165DataRank · unranked

2 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, David R. Gandara, Fred R. Hirsch, Philip C. Mack +14 more

29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC)

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0029

N/A

0.104DataRank · unranked

1 citations

Xing Hua, Khaled Tolba, David Fabrizio, Lee A. Albacker, Ryan Brennick +11 more

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9075

N/A

0.104DataRank · unranked

1 citations

Mary W. Redman, Konstantin H. Dragnev, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi +7 more

Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9121

N/A

0.104DataRank · unranked

1 citations

Frederick H. Wilson, Sarah B. Goldberg, Anne C. Chiang, Brian S. Henick, Elin Rowen +10 more

Data from High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor

(2023)10.1158/0008-5472.c.6494705

N/A

0DataRank · unranked

0 citations

Marie Wislez, Jie Zhang, Kentaro Iwanaga, Jennifer Dackor, Amy E. Hanna +14 more

The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9035

N/A

0DataRank · unranked

0 citations

Mary W. Redman, David Kozono, Sam Callis, Hanna Tukachinsky, Khaled Tolba +14 more

Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer

Translational Oncology(2024)10.1016/j.tranon.2024.102108

N/A

0DataRank · unranked

7 citations

Bing Ma, Gail Schor, Madison Bailey, Brianna Pham, Inyoung Cho +9 more

Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

(2024)10.1158/1078-0432.c.7181344.v1

Top 100%

0DataRank

Top 100%0 citations

Jiexin Zhang, Dzifa Y. Duose, Edgar Gonzalez‐Kozlova, Mary W. Redman, Hong Chen +42 more

Enhancing Immunotherapy Outcomes: Spatial Multi-Omics Models for Non-Small Cell Lung Cancer

Research Square(2024)10.21203/rs.3.rs-4966123/v1

N/A

0DataRank · unranked

0 citations

Thazin Nwe Aung, James Monkman, Jonathan Warrell, Katherine E. Bates, Niki Gavrielatou +10 more

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100205

N/A

0DataRank · unranked

84 citations

Roy S. Herbst, Gilberto de Castro, Rina Hui, Nir Peled, Dong‐Wan Kim +12 more

SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9623

Top 100%

0DataRank

Top 100%0 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6543

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Qian Lü, Katherine Minichiello, Roy S. Herbst, David R. Gandara +14 more

Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9046

N/A

0DataRank · unranked

0 citations

Dzifa Y. Duose, Jiexin Zhang, Mary W. Redman, Rossana Lazcano Segura, Mario L. Marques‐Piubelli +14 more

Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9044

N/A

0DataRank · unranked

0 citations

Hsin-Hui Huang, Mary W. Redman, Roy S. Herbst, Scott Gettinger, Lyudmila Bazhenova +15 more

Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005025

N/A

0DataRank · unranked

10 citations

Franz Villarroel‐Espíndola, Ila Datar, Miguel F. Sanmamed, Jovian Yu, Shruti Desai +8 more

Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.06.007

N/A

0DataRank · unranked

13 citations

Niki Gavrielatou, Leena McCann, Saba Shafi, Myrto Moutafi, Sandra Martínez-Morilla +10 more

Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2690

N/A

0DataRank · unranked

5 citations

Charles D. Blanke, Ellen V. Sigal, Roy S. Herbst

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.10.015

N/A

0DataRank · unranked

11 citations

Mary W. Redman, Karen Kelly, S. Waqar, Francisco Robert, Gauri Kiefer +6 more

Data from High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor

(2023)10.1158/0008-5472.c.6494705.v1

N/A

0DataRank · unranked

0 citations

Marie Wislez, Jie Zhang, Kentaro Iwanaga, Jennifer Dackor, Amy E. Hanna +14 more

Roy S. Herbst

Indexed papers

Top data-sharing exemplar

Papers